Urine DNA test could spot bladder cancer early in lynch syndrome patients
NCT ID NCT06218433
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing whether a urine test that looks for tumor DNA can find bladder and urinary tract cancers early in people with Lynch syndrome, a genetic condition that raises cancer risk. About 200 participants aged 50–75 will provide urine samples and be followed for one year to see if the test accurately detects cancers. If successful, this could lead to a simple, non-invasive screening method for this high-risk group.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYNCH SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tampere University Hospital and Tampere University
RECRUITINGTampere, Finland
Contact
Contact
Contact
Contact
Contact
-
Vancouver Prostate Centre
RECRUITINGVancouver, Canada
Contact
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new nucleotide analogue boost cancer treatment?
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- Can a Two-Drug attack shrink Hard-to-Treat bladder tumors?
- Can a walking routine alter cancer biomarkers? new trial investigates
- Could a lighter immunotherapy schedule keep advanced cancers in check?
- New biologic drug DBC-664 takes aim at Hard-to-Treat cancers